Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 618

1.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.

PMID:
18316689
2.

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.

Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY.

Neuro Oncol. 2009 Oct;11(5):550-5. doi: 10.1215/15228517-2009-006. Epub 2009 Mar 30.

3.

Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.

Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, Zhang Z, Lassman AB, Abrey LE, Gutin PH.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):636-42. doi: 10.1016/j.ijrobp.2012.05.031. Epub 2012 Jul 3.

PMID:
22765876
4.

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.

Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J, Bredel M.

Cancer. 2010 Nov 15;116(22):5297-305. doi: 10.1002/cncr.25462.

5.

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY.

Neuro Oncol. 2007 Jul;9(3):354-63. Epub 2007 Apr 23.

6.

Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.

Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P.

Can J Neurol Sci. 2013 Mar;40(2):241-6.

PMID:
23419575
7.

Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.

Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY.

Cancer. 2013 Oct 1;119(19):3479-88. doi: 10.1002/cncr.28210. Epub 2013 Jul 2.

8.

Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.

Chamberlain MC.

Cancer. 2010 Sep 1;116(17):3988-99. doi: 10.1002/cncr.25256. Review.

9.

Bevacizumab is active as a single agent against recurrent malignant gliomas.

Agha CA, Ibrahim S, Hassan A, Elias DA, Fathallah-Shaykh HM.

Anticancer Res. 2010 Feb;30(2):609-11.

PMID:
20332478
10.

Bevacizumab in recurrent high-grade pediatric gliomas.

Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.

Neuro Oncol. 2010 Sep;12(9):985-90. doi: 10.1093/neuonc/noq033. Epub 2010 Apr 2.

11.

Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.

Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, Ono K.

Neuro Oncol. 2013 Jun;15(6):650-5. doi: 10.1093/neuonc/not020. Epub 2013 Mar 3.

12.

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T.

J Neurooncol. 2009 Feb;91(3):329-36. doi: 10.1007/s11060-008-9718-y. Epub 2008 Oct 25.

PMID:
18953493
13.

Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma.

Wiestler B, Radbruch A, Osswald M, Combs SE, Jungk C, Winkler F, Bendszus M, Unterberg A, Platten M, Wick W, Wick A.

J Neurooncol. 2014 Mar;117(1):85-92. doi: 10.1007/s11060-013-1356-3. Epub 2014 Jan 24.

PMID:
24458956
14.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.

15.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Mrugala MM.

Neurology. 2009 Feb 24;72(8):773; author reply 773-4. No abstract available.

PMID:
19248218
16.

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ.

Clin Cancer Res. 2008 Nov 1;14(21):7068-73. doi: 10.1158/1078-0432.CCR-08-0260.

17.

Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.

Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS.

Neurosurgery. 1994 Sep;35(3):378-88; discussion 388.

PMID:
7800129
18.

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.

Pediatr Blood Cancer. 2013 May;60(5):776-82. doi: 10.1002/pbc.24297. Epub 2012 Sep 13.

PMID:
22976922
19.

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS.

Anticancer Res. 2013 Apr;33(4):1657-60.

PMID:
23564811
20.

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB.

Neurology. 2009 Oct 13;73(15):1200-6. doi: 10.1212/WNL.0b013e3181bc0184.

Supplemental Content

Support Center